WHO ICTRP trial
Singel-arm, exploratory clinical study of SBRT sequential TACE combined with…
ChiCTR2300072570 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300072570 |
|---|---|
| Public title | Singel-arm, exploratory clinical study of SBRT sequential TACE combined with lenvatinib and sintilimab in the treatment of unresectable HCC with type III PVTT. |
| Scientific title | Singel-arm, exploratory clinical study of SBRT sequential TACE combined with lenvatinib and sintilimab in the treatment of unresectable HCC with type III PVTT. |
| Primary sponsor | Fujian Provincial Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | hepatocellular carcinoma |
| Interventions | treatment group:transcatheter arterial chemoembolization + lenvatinib + Sintilimab + radiotherapy |
| Registration date | Jun 16, 2023 |
| Target size | treatment group:70 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: